DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Anoma Ranaweera B.V.Sc; PhD (Clinical Biochemistry, University of Liverpool, UK); Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, June 2016.
In March 2016, the US FDA approved the biological treatment ixekizumab (TALTZ™ Eli Lilly, Indiana, USA) for the treatment of psoriasis. In November 2017, they also approved it for active psoriatic arthritis.
In April 2016, the European Medicines Agency also granted marketing authorization of ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) with neutralizing activity against IL-17A. See Interleukin-17 in inflammatory skin disorders.
It is produced by recombinant DNA technology in a mammalian cell line and is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each.
Ixekizumab is used for treating moderate to severe plaque psoriasis in adult patients that are candidates for systemic therapy (medicine absorbed into the bloodstream) or phototherapy (ultraviolet light treatment). It has also been demonstrated to improve scalp psoriasis and nail psoriasis.
Potential drug interactions with ixekizumab
Ixekizumab is very well tolerated. Most common (≥ 1%) adverse reactions associated with ixekizumab treatment are:
Less common adverse reactions (< 1%) include:
The safety and effectiveness of ixekizumab has not been established in paediatric patients (<18 years of age).
Clinical studies of ixekizumab did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients.
No formal studies have been conducted on the effect of hepatic or renal impairment on the pharmacokinetics of ixekizumab.
If you are not based in New Zealand, we suggest you refer to your national drug approval agency for further information about medicines (eg, the Australian Therapeutic Goods Administration and the US Food and Drug Administration) or a national or state-approved formulary (eg, the New Zealand Formulary and New Zealand Formulary for Children and the British National Formulary and British National Formulary for Children).
© 2021 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.